ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $9.95 million. The enterprise value is $11.63 million.
| Market Cap | 9.95M |
| Enterprise Value | 11.63M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, after market close.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 12.05 million shares outstanding. The number of shares has increased by 194.36% in one year.
| Shares Outstanding | 12.05M |
| Shares Change (YoY) | +194.36% |
| Shares Change (QoQ) | +124.56% |
| Owned by Insiders (%) | 23.63% |
| Owned by Institutions (%) | 3.32% |
| Float | 8.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 392.49 |
| Forward PS | n/a |
| PB Ratio | 1.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 458.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.27, with a Debt / Equity ratio of 0.31.
| Current Ratio | 0.27 |
| Quick Ratio | 0.25 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.96 |
Financial Efficiency
Return on equity (ROE) is -202.80% and return on invested capital (ROIC) is -95.60%.
| Return on Equity (ROE) | -202.80% |
| Return on Assets (ROA) | -92.00% |
| Return on Capital (ROIC) | -95.60% |
| Revenue Per Employee | $1,335 |
| Profits Per Employee | -$664,470 |
| Employee Count | 19 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $256,006 in taxes.
| Income Tax | 256,006 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.33% in the last 52 weeks. The beta is 0.85, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -80.33% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.14 |
| Relative Strength Index (RSI) | 50.64 |
| Average Volume (20 Days) | 120,999 |
Short Selling Information
The latest short interest is 227,867, so 1.89% of the outstanding shares have been sold short.
| Short Interest | 227,867 |
| Short Previous Month | 369,970 |
| Short % of Shares Out | 1.89% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 1.72 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $25,363 and -$12.62 million in losses. Loss per share was -$2.25.
| Revenue | 25,363 |
| Gross Profit | -216,715 |
| Operating Income | -9.75M |
| Pretax Income | -12.37M |
| Net Income | -12.62M |
| EBITDA | -9.22M |
| EBIT | -9.25M |
| Loss Per Share | -$2.25 |
Balance Sheet
The company has $734,918 in cash and $2.41 million in debt, giving a net cash position of -$1.68 million or -$0.14 per share.
| Cash & Cash Equivalents | 734,918 |
| Total Debt | 2.41M |
| Net Cash | -1.68M |
| Net Cash Per Share | -$0.14 |
| Equity (Book Value) | 7.79M |
| Book Value Per Share | 0.65 |
| Working Capital | -4.84M |
Cash Flow
In the last 12 months, operating cash flow was -$3.21 million and capital expenditures -$21,201, giving a free cash flow of -$3.23 million.
| Operating Cash Flow | -3.21M |
| Capital Expenditures | -21,201 |
| Free Cash Flow | -3.23M |
| FCF Per Share | -$0.33 |
Margins
Gross margin is -854.45%, with operating and profit margins of -38,460.41% and -49,776.99%.
| Gross Margin | -854.45% |
| Operating Margin | -38,460.41% |
| Pretax Margin | -48,767.62% |
| Profit Margin | -49,776.99% |
| EBITDA Margin | -36,368.91% |
| EBIT Margin | -36,460.87% |
| FCF Margin | -12,745.24% |
Dividends & Yields
ABVC BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -194.36% |
| Shareholder Yield | -194.36% |
| Earnings Yield | -126.82% |
| FCF Yield | -32.47% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
ABVC BioPharma has an Altman Z-Score of -8.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.37 |
| Piotroski F-Score | 2 |